Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …

The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular
studies, remains largely based on conventional prognostic scores [International Prognostic …

Abstract Between April 1988 and July 1998, 510 patients with myelodysplastic syndromes
(MDS) underwent unrelated donor bone marrow transplantation (BMT) facilitated by the …

The myelodysplastic syndromes (MDSs) are common, acquired, clinically challenging
hematologic conditions that are characterized by bone marrow failure and a risk of …

1Department of Hematology, University of Pavia School of Medicine, IRCCS Policlinico S.
Matteo, Pavia; 2Dept. of Hematology, University Tor Vergata, Rome; 3Division of …

This study investigated the feasibility of allogeneic (alloSCT) and autologous stem cell
transplantation (ASCT) as postconsolidation therapy for patients with myelodysplastic …

The myelodysplastic syndrome (MDS) includes a diverse group of clonal and potentially
malignant bone marrow disorders characterized by ineffective and inadequate …

Background Allogeneic stem cell transplantation is usually considered the only curative
treatment option for patients with advanced or transformed myelodysplastic syndromes in …

Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by
inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of …